1887

Chapter 8 : Bacterial Pathogens

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Bacterial Pathogens, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch8-1.gif /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch8-2.gif

Abstract:

Bacterial endotoxins are heat-stable components of the Gram-negative outer membrane that are released after a bacterial cell lyses and are also continuously shed by viable bacteria. Endotoxins cause systemic inflammatory responses and are associated with sepsis as well as chronic inflammation (1). The outer membrane of Gram-negative bacteria is covered up to 75% by lipopolysaccharides (LPSs); the remainder consists of proteins that primarily serve as channels for the entry and exit of molecules or as structures that mediate interactions with the environment (2). A LPS is composed of three parts—lipid A, core polysaccharide, and a glycan, typically O antigen. Lipid A is the ligand that stimulates inflammation by binding to receptors on the host cell surface as well as intracellular membranes and cytoplasm (3). Many bacterial pathogens, such as , , , and , synthesize an alternative form of lipid A that is less stimulatory in the mammalian host and significantly dampens the early host inflammatory responses, thus facilitating the establishment of disease.

Citation: McCarthy T, Patel A, Anderson P, Anderson D. 2017. Bacterial Pathogens, p 163-185. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch8
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819637.ch8
1. Zielen S, Trischler J, Schubert R. 2015. Lipopolysaccharide challenge: immunological effects and safety in humans. Expert Rev Clin Immunol 11:409418.[PubMed]
2. Molinaro A, Holst O, Di Lorenzo F, Callaghan M, Nurisso A, D'Errico G, Zamyatina A, Peri F, Berisio R, Jerala R, Jiménez-Barbero J, Silipo A, Martín-Santamaría S. 2015. Chemistry of lipid A: at the heart of innate immunity. Chemistry 21:500519.[PubMed]
3. Morgenroth J, Kaufmann M. 1912. Arzneifestigkeit bei Bakterien (Pneumokokken). Z Immunit Exp Ther 15:610
4. Costa TR, Felisberto-Rodrigues C, Meir A, Prevost MS, Redzej A, Trokter M, Waksman G. 2015. Secretion systems in Gram-negative bacteria: structural and mechanistic insights. Nat Rev Microbiol 13:343359.[PubMed]
5. Personnic N, Bärlocher K, Finsel I, Hilbi H. 2016. Subversion of retrograde trafficking by translocated pathogen effectors. Trends Microbiol 24:450462.[PubMed]
6. Valentini M, Filloux A. 2016. Biofilms and cyclic di-GMP (c-di-GMP) signaling: lessons from Pseudomonas aeruginosa and other bacteria. J Biol Chem 291:1254712555.[PubMed]
7. Latorre I, Domínguez J. 2015. Dormancy antigens as biomarkers of latent tuberculosis infection. EBioMedicine 2:790791.[PubMed]
8. Dhariwala MO, Anderson DM. 2014. Bacterial programming of host responses: coordination between type I interferon and cell death. Front Microbiol 5:545.[PubMed]
9. Scales BS, Dickson RP, Huffnagle GB. 2016. A tale of two sites: how inflammation can reshape the microbiomes of the gut and lungs. J Leukoc Biol 100:943950.[PubMed]
10. Winchell CG, Steele S, Kawula T, Voth DE. 2016. Dining in: intracellular bacterial pathogen interplay with autophagy. Curr Opin Microbiol 29:914.[PubMed]
11. Lai XH, Xu Y, Chen XM, Ren Y. 2015. Macrophage cell death upon intracellular bacterial infection. Macrophage Houst 2:e779.[PubMed]
12. Ucker DS. 2016. Exploiting death: apoptotic immunity in microbial pathogenesis. Cell Death Differ 23:990996.[PubMed]
13. Abebe M, Kim L, Rook G, Aseffa A, Wassie L, Zewdie M, Zumla A, Engers H, Andersen P, Doherty TM. 2011. Modulation of cell death by M. tuberculosis as a strategy for pathogen survival. Clin Dev Immunol 2011:678570.[PubMed]
14. Chow SH, Deo P, Naderer T. 2016. Macrophage cell death in microbial infections. Cell Microbiol 18:466474.[PubMed]
15. Wallach D, Kang TB, Dillon CP, Green DR. 2016. Programmed necrosis in inflammation: toward identification of the effector molecules. Science 352:aaf2154.[PubMed]
16. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. 2014. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15:135147.[PubMed]
17. Thammavongsa V, Kim HK, Missiakas D, Schneewind O. 2015. Staphylococcal manipulation of host immune responses. Nat Rev Microbiol 13:529543.[PubMed]
18. Thompson KA, Bennett AM, Walker JT. 2011. Aerosol survival of Staphylococcus epidermidis. J Hosp Infect 78:216220.[PubMed]
19. Lancefield RC. 1933. A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med 57:571595.[PubMed]
20. Dillon HC Jr. 1979. Post-streptococcal glomerulonephritis following pyoderma. Rev Infect Dis 1:935945.[PubMed]
21. Centor RM, Meier FA, Dalton HP. 1986. Diagnostic decision: throat cultures and rapid tests for diagnosis of group A streptococcal pharyngitis. Ann Intern Med 105:892899.[PubMed]
22. Quinn RW. 1989. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. Rev Infect Dis 11:928953.[PubMed]
23. Venezio FR, Gullberg RM, Westenfelder GO, Phair JP, Cook FV. 1986. Group G streptococcal endocarditis and bacteremia. Am J Med 81:2934.[PubMed]
24. Patterson M. 1996. Chapter 13, Streptococcus. In Medical Microbiology, 4th ed. University of Texas Medical Branch at Galveston, Galveston, TX.
25. Orefici G, Cardona F, Cox C, Cunningham M. 2016. Pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections (PANDAS). University of Oklahoma Health Sciences Center, Oklahoma City, OK.
26. Lynch JP III, Zhanel GG. 2009. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 30:189209.[PubMed]
27. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, Finkelstein JA. 2011. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 29:33983412.[PubMed]
28. Centers for Disease Control and Prevention. 2012. Epidemiology and prevention of vaccine-preventable diseases, vol 2. Public Health Foundation, Washington, DC.
29. Immunization Practice Advisory Committee. 1997. Prevention of pneumococcal disease: recommendation of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 46:124.
30. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, Miller GB, Witcomb MA, Isaäcson M, Ward JI, Austrian R. 1978. Emergence of multiply resistant pneumococci. N Engl J Med 299:735740.[PubMed]
31. Pérez JL, Linares J, Bosch J, López de Goicoechea MJ, Martín R. 1987. Antibiotic resistance of Streptococcus pneumoniae in childhood carriers. J Antimicrob Chemother 19:278280.[PubMed]
32. Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, Goldblatt D, O'Brien KL, Whitney CG. 2014. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 33(Suppl 2):S109S118.[PubMed]
33. Hochman M, Cohen PA. 2015. Reconsidering guidelines on the use of pneumococcal vaccines in adults 65 years or older. JAMA Intern Med 175:18951896.[PubMed]
34. Lechner S, Mayr R, Francis KP, Prüss BM, Kaplan T, Wiessner-Gunkel E, Stewart GS, Scherer S. 1998. Bacillus weihenstephanensis sp. nov. is a new psychrotolerant species of the Bacillus cereus group. Int J Syst Evol Microbiol 48:13731382.[PubMed]
35. Berger T, Kassirer M, Aran AA. 2014. Injectional anthrax—new presentation of an old disease. Euro Surveill 19:20877.[PubMed]
36. Friebe S, van der Goot FG, Bürgi J. 2016. The ins and outs of anthrax toxin. Toxins (Basel) 8:69.[PubMed]
37. Williamson ED, Dyson EH. 2015. Anthrax prophylaxis: recent advances and future directions. Front Microbiol 6:1009.[PubMed]
38. Wang Q, Chang BJ, Riley TV. 2010. Erysipelothrix rhusiopathiae. Vet Microbiol 140:405417.[PubMed]
39. Wexler HM. 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20:593621.[PubMed]
40. Sóki J, Hedberg M, Patrick S, Bálint B, Herczeg R, Nagy I, Hecht DW, Nagy E, Urbán E. 2016. Emergence and evolution of an international cluster of MDR Bacteroides fragilis isolates. J Antimicrob Chemother 71:24412448.[PubMed]
41. Rodriguez C, Van Broeck J, Taminiau B, Delmée M, Daube G. 2016. Clostridium difficile infection: early history, diagnosis and molecular strain typing methods. Microb Pathog 97:5978.[PubMed]
42. Nelson EJ, Harris JB, Morris JG Jr, Calderwood SB, Camilli A. 2009. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat Rev Microbiol 7:693702.[PubMed]
43. Bishop AL, Camilli A. 2011. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines 10:7994.[PubMed]
44. Huehn S, Eichhorn C, Urmersbach S, Breidenbach J, Bechlars S, Bier N, Alter T, Bartelt E, Frank C, Oberheitmann B, Gunzer F, Brennholt N, Böer S, Appel B, Dieckmann R, Strauch E. 2014. Pathogenic vibrios in environmental, seafood and clinical sources in Germany. Int J Med Microbiol 304:843850.[PubMed]
45. Tang HJ, Chen CC, Lai CC, Zhang CC, Weng TC, Chiu YH, Toh HS, Chiang SR, Yu WL, Ko WC, Chuang YC. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect, in press.[PubMed]
46. Gölz G, Rosner B, Hofreuter D, Josenhans C, Kreienbrock L, Löwenstein A, Schielke A, Stark K, Suerbaum S, Wieler LH, Alter T. 2014. Relevance of Campylobacter to public health—the need for a One Health approach. Int J Med Microbiol 304:817823.[PubMed]
47. Wieczorek K, Osek J. 2013. Antimicrobial resistance mechanisms among Campylobacter. BioMed Res Int 2013:340605.[PubMed]
48. Keilberg D, Ottemann KM. 2016. How Helicobacter pylori senses, targets and interacts with the gastric epithelium. Environ Microbiol 18:791806.[PubMed]
49. Kim IJ, Blanke SR. 2012. Remodeling the host environment: modulation of the gastric epithelium by the Helicobacter pylori vacuolating toxin (VacA). Front Cell Infect Microbiol 2:37.[PubMed]
50. Safavi M, Sabourian R, Foroumadi A. 2016. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases 4:519.[PubMed]
51. Majowicz SE, Scallan E, Jones-Bitton A, Sargeant JM, Stapleton J, Angulo FJ, Yeung DH, Kirk MD. 2014. Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis 11:447455.[PubMed]
52. Rahal EA, Fadlallah SM, Nassar FJ, Kazzi N, Matar GM. 2015. Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype. Front Cell Infect Microbiol 5:24.[PubMed]
53. Agger M, Scheutz F, Villumsen S, Mølbak K, Petersen AM. 2015. Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J Antimicrob Chemother 70:24402446.[PubMed]
54. Franzin FM, Sircili MP. 2015. Locus of enterocyte effacement: a pathogenicity island involved in the virulence of enteropathogenic and enterohemorragic Escherichia coli subjected to a complex network of gene regulation. BioMed Res Int 2015:534738.[PubMed]
55. Ochoa TJ, Contreras CA. 2011. Enteropathogenic E. coli (EPEC) infection in children. Curr Opin Infect Dis 24:478483.[PubMed]
56. O'Ryan M, Vidal R, del Canto F, Carlos Salazar J, Montero D. 2015. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Hum Vaccin Immunother 11:601619.[PubMed]
57. Kariuki S, Gordon MA, Feasey N, Parry CM. 2015. Antimicrobial resistance and management of invasive Salmonella disease. Vaccine 33(Suppl 3):C21C29.[PubMed]
58. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. 2015. Global burden of invasive nontyphoidal Salmonella disease, 2010(1). Emerg Infect Dis 21:941949.[PubMed]
59. Kariuki S, Onsare RS. 2015. Epidemiology and genomics of invasive nontyphoidal Salmonella infections in Kenya. Clin Infect Dis 61(Suppl 4):S317S324.[PubMed]
60. Andrews JR, Ryan ET. 2015. Diagnostics for invasive Salmonella infections: current challenges and future directions. Vaccine 33(Suppl 3):C8C15.[PubMed]
61. Watson CH, Edmunds WJ. 2015. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination. Vaccine 33(Suppl 3):C42C54.[PubMed]
62. Tennant SM, Levine MM. 2015. Live attenuated vaccines for invasive Salmonella infections. Vaccine 33(Suppl 3):C36C41.[PubMed]
63. Valentin-Weigand P, Heesemann J, Dersch P. 2014. Unique virulence properties of Yersinia enterocolitica O:3—an emerging zoonotic pathogen using pigs as preferred reservoir host. Int J Med Microbiol 304:824834.[PubMed]
64. Cui Y, Yu C, Yan Y, Li D, Li Y, Jombart T, Weinert LA, Wang Z, Guo Z, Xu L, Zhang Y, Zheng H, Qin N, Xiao X, Wu M, Wang X, Zhou D, Qi Z, Du Z, Wu H, Yang X, Cao H, Wang H, Wang J, Yao S, Rakin A, Li Y, Falush D, Balloux F, Achtman M, Song Y, Wang J, Yang R. 2013. Historical variations in mutation rate in an epidemic pathogen, Yersinia pestis. Proc Natl Acad Sci USA 110:577582.[PubMed]
65. Butler T. 2013. Plague gives surprises in the first decade of the 21st century in the United States and worldwide. Am J Trop Med Hyg 89:788793.[PubMed]
66. Wang H, Cui Y, Wang Z, Wang X, Guo Z, Yan Y, Li C, Cui B, Xiao X, Yang Y, Qi Z, Wang G, Wei B, Yu S, He D, Chen H, Chen G, Song Y, Yang R. 2011. A dog-associated primary pneumonic plague in Qinghai Province, China. Clin Infect Dis 52:185190.[PubMed]
67. Organization WH. 2016. Plague around the world, 2010–2015. Wkly Epidemiol Rec 91:8993.[PubMed]
68. Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E, Courvalin P. 1997. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337:677681.[PubMed]
69. Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, Courvalin P, Carniel E. 2001. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 7:4348.[PubMed]
70. Pollitzer R. 1954. Plague. World Health Organization, Geneva, Switzerland.
71. Li YF, Li DB, Shao HS, Li HJ, Han YD. 2016. Plague in China 2014-All sporadic case report of pneumonic plague. BMC Infect Dis 16:85.[PubMed]
72. Feodorova VA, Motin VL. 2012. Plague vaccines: current developments and future perspectives. Emerg Microbes Infect 1:e36.[PubMed]
73. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SE, Oyston PC, Easterbrook T, Reddin KM, Robinson A, Titball R. 1995. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12:223230.[PubMed]
74. Heath DG, Anderson GW Jr, Mauro JM, Welkos SL, Andrews GP, Adamovicz J, Friedlander AM. 1998. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16:11311137.[PubMed]
75. Frank KM, Schneewind O, Shieh WJ. 2011. Investigation of a researcher's death due to septicemic plague. N Engl J Med 364:25632564.[PubMed]
76. Quenee LE, Hermanas TM, Ciletti N, Louvel H, Miller NC, Elli D, Blaylock B, Mitchell A, Schroeder J, Krausz T, Kanabrocki J, Schneewind O. 2012. Hereditary hemochromatosis restores the virulence of plague vaccine strains. J Infect Dis 206:10501058.[PubMed]
77. Franzetti F, Cernuschi M, Esposito R, Moroni M. 1992. Pseudomonas infections in patients with AIDS and AIDS-related complex. J Intern Med 231:437443.[PubMed]
78. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2:10511060.[PubMed]
79. Williams BJ, Dehnbostel J, Blackwell TS. 2010. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 15:10371056.[PubMed]
80. Safdar N, Crnich CJ, Maki DG. 2005. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 50:725739, discussion 739–741.[PubMed]
81. Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Döring G, Tümmler B. 2009. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180:138145.[PubMed]
82. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock RE, Speert DP. 2002. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 196:109118.[PubMed]
83. Zhang L, Mah TF. 2008. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 190:44474452.[PubMed]
84. Fricks-Lima J, Hendrickson CM, Allgaier M, Zhuo H, Wiener-Kronish JP, Lynch SV, Yang K. 2011. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents 37:309315.[PubMed]
85. Huber P, Basso P, Reboud E, Attrée I. Pseudomonas aeruginosa renews its virulence factors. Environ Microbiol Rep, in press.[PubMed]
86. Falagas ME, Bliziotis IA. 2007. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29:630636.[PubMed]
87. Galyov EE, Brett PJ, DeShazer D. 2010. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol 64:495517.[PubMed]
88. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. 2005. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 43:970972.[PubMed]
89. Yan Z, Yang J, Hu R, Hu X, Chen K. 2016. Acinetobacter baumannii infection and IL-17 mediated immunity. Mediators Inflamm 2016:9834020.[PubMed]
90. Rice LB. 2009. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 12:476481.[PubMed]
91. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. 1998. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280:635637.[PubMed]
92. Mooi FR, Bruisten S, Linde I, Reubsaet F, Heuvelman K, van der Lee S, King AJ. 2012. Characterization of Bordetella holmesii isolates from patients with pertussis-like illness in The Netherlands. FEMS Immunol Med Microbiol 64:289291.[PubMed]
93. Yesmin K, Mamun K, Shamsazzaman S, Chowdhury A, Khatun K, Alam J. 2010. Isolation of potential pathogenic bacteria from nasopharynx from patients having cough for more than two weeks. Bangladesh J Med Microbiol 4:1318
94. Prasad SM, Yin Y, Rodzinski E, Tuomanen EI, Masure HR. 1993. Identification of a carbohydrate recognition domain in filamentous hemagglutinin from Bordetella pertussis. Infect Immun 61:27802785.[PubMed]
95. Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP, Stibitz ES. 2014. Pertussis pathogenesis—what we know and what we don't know. J Infect Dis 209:982985.[PubMed]
96. Carbonetti NH. 2016. Bordetella pertussis: new concepts in pathogenesis and treatment. Curr Opin Infect Dis 29:287294.[PubMed]
97. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. 2016. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 29:449486.[PubMed]
98. Paczosa MK, Mecsas J. 2016. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev 80:629661.[PubMed]
99. Schielke S, Frosch M, Kurzai O. 2010. Virulence determinants involved in differential host niche adaptation of Neisseria meningitidis and Neisseria gonorrhoeae. Med Microbiol Immunol (Berl) 199:185196.[PubMed]
100. Dillon JA, Yeung KH. 1989. β-Lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev 2(Suppl):S125S133.[PubMed]
101. Tapsall JW. 2009. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 22:8791.[PubMed][CrossRef]
102. Cartwright KA, Stuart JM, Jones DM, Noah ND. 1987. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99:591601.[PubMed]
103. Stephens DS. 1999. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 353:941942.[PubMed]
104. Singh K. 2009. Laboratory-acquired infections. Clin Infect Dis 49:142147.[PubMed]
105. Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ Emergency Medicine Animal Bite Infection Study Group. 1999. Bacteriologic analysis of infected dog and cat bites. N Engl J Med 340:8592.[PubMed]
106. Dworkin MS, Anderson DE Jr, Schwan TG, Shoemaker PC, Banerjee SN, Kassen BO, Burgdorfer W. 1998. Tick-borne relapsing fever in the northwestern United States and southwestern Canada. Clin Infect Dis 26:122131.[PubMed]
107. Vinetz JM. 2001. Leptospirosis. Curr Opin Infect Dis 14:527538.[PubMed]
108. Vijayachari P, Sugunan AP, Shriram AN. 2008. Leptospirosis: an emerging global public health problem. J Biosci 33:557569.[PubMed]
109. Ko AI, Galvão Reis M, Ribeiro Dourado CM, Johnson WD Jr, Riley LW Salvador Leptospirosis Study Group. 1999. Urban epidemic of severe leptospirosis in Brazil. Lancet 354:820825.[PubMed]
110. Vinetz JM, Glass GE, Flexner CE, Mueller P, Kaslow DC. 1996. Sporadic urban leptospirosis. Ann Intern Med 125:794798.[PubMed]
111. Ko AI, Goarant C, Picardeau M. 2009. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol 7:736747.[PubMed]
112. Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CR. 2007. Pathology and pathophysiology of pulmonary manifestations in leptospirosis. Braz J Infect Dis 11:142148.[PubMed]
113. Levett PN. 2001. Leptospirosis. Clin Microbiol Rev 14:296326.[PubMed]
114. Deretic V, Vergne I, Chua J, Master S, Singh SB, Fazio JA, Kyei G. 2004. Endosomal membrane traffic: convergence point targeted by Mycobacterium tuberculosis and HIV. Cell Microbiol 6:9991009.[PubMed]
115. Kumar D, Rao KV. 2011. Regulation between survival, persistence, and elimination of intracellular mycobacteria: a nested equilibrium of delicate balances. Microbes Infect 13:121133.[PubMed]
116. Kaufmann SH, McMichael AJ. 2005. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11(Suppl):S33S44.[PubMed]
117. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:11731180.[PubMed]
118. Rodrigues LC, Lockwood DN. 2011. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 11:464470.[PubMed]
119. Pike RM. 1976. Laboratory-associated infections: summary and analysis of 3921 cases. Health Lab Sci 13:105114.[PubMed]
120. Ollé-Goig JE, Canela-Soler J. 1987. An outbreak of Brucella melitensis infection by airborne transmission among laboratory workers. Am J Public Health 77:335338.[PubMed]
121. Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. 1995. Global data on blindness. Bull World Health Organ 73:115121.[PubMed]
122. Harkinezhad T, Geens T, Vanrompay D. 2009. Chlamydophila psittaci infections in birds: a review with emphasis on zoonotic consequences. Vet Microbiol 135:6877.[PubMed]
123. Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. 2004. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 72:18431855.[PubMed]
124. Allerberger F, Wagner M. 2010. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect 16:1623.[PubMed]
125. Hoffman AD, Gall KL, Norton DM, Wiedmann M. 2003. Listeria monocytogenes contamination patterns for the smoked fish processing environment and for raw fish. J Food Prot 66:5260.[PubMed]
126. Smith B, Kemp M, Ethelberg S, Schiellerup P, Bruun BG, Gerner-Smidt P, Christensen JJ. 2009. Listeria monocytogenes: maternal-foetal infections in Denmark 1994–2005. Scand J Infect Dis 41:2125.[PubMed]
127. Cone LA, Somero MS, Qureshi FJ, Kerkar S, Byrd RG, Hirschberg JM, Gauto AR. 2008. Unusual infections due to Listeria monocytogenes in the Southern California Desert. Int J Infect Dis 12:578581.[PubMed]
128. Hof H. 2003. Therapeutic options. FEMS Immunol Med Microbiol 35:203205.[PubMed]
129. Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD. 2006. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 66:10961104.[PubMed]
130. Datta SK, Okamoto S, Hayashi T, Shin SS, Mihajlov I, Fermin A, Guiney DG, Fierer J, Raz E. 2006. Vaccination with irradiated Listeria induces protective T cell immunity. Immunity 25:143152.[PubMed]
131. Bechah Y, Capo C, Raoult D, Mege JL. 2008. Infection of endothelial cells with virulent Rickettsia prowazekii increases the transmigration of leukocytes. J Infect Dis 197:142147.[PubMed]
132. Johnson JE III, Kadull PJ. 1967. Rocky Mountain spotted fever acquired in a laboratory. N Engl J Med 277:842847.[PubMed]
133. Oster CN, Burke DS, Kenyon RH, Ascher MS, Harber P, Pedersen CE Jr. 1977. Laboratory-acquired Rocky Mountain spotted fever. The hazard of aerosol transmission. N Engl J Med 297:859863.[PubMed]
134. Demma LJ, Traeger MS, Nicholson WL, Paddock CD, Blau DM, Eremeeva ME, Dasch GA, Levin ML, Singleton J Jr, Zaki SR, Cheek JE, Swerdlow DL, McQuiston JH. 2005. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 353:587594.[PubMed]
135. Nicholson WL, Allen KE, McQuiston JH, Breitschwerdt EB, Little SE. 2010. The increasing recognition of rickettsial pathogens in dogs and people. Trends Parasitol 26:205212.[PubMed]
136. Watt G, Parola P. 2003. Scrub typhus and tropical rickettsioses. Curr Opin Infect Dis 16:429436.[PubMed]
137. Truchan HK, Seidman D, Carlyon JA. 2013. Breaking in and grabbing a meal: Anaplasma phagocytophilum cellular invasion, nutrient acquisition, and promising tools for their study. Microbes Infect 15:10171025.[PubMed]
138. Sanchez E, Vannier E, Wormser GP, Hu LT. 2016. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA 315:17671777.[PubMed]
139. Rikihisa Y. 2015. Molecular pathogenesis of Ehrlichia chaffeenis infection. Annu Rev Microbiol 69:283304.[PubMed]
140. Maurin M, Raoult D. 1999. Q fever. Clin Microbiol Rev 12:518553.[PubMed]
141. Oyston PC, Davies C. 2011. Q fever: the neglected biothreat agent. J Med Microbiol 60:921.[PubMed]
142. Johnson JE III, Kadull PJ. 1966. Laboratory-acquired Q fever. A report of fifty cases. Am J Med 41:391403.[PubMed]
143. Keim P, Johansson A, Wagner DM. 2007. Molecular epidemiology, evolution, and ecology of Francisella. Ann N Y Acad Sci 1105:3066.[PubMed]
144. Eigelsbach HT, Downs CM. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol 87:415425.[PubMed]
145. Pechous RD, McCarthy TR, Zahrt TC. 2009. Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev 73:684711.[PubMed]
146. Brenner DJ, Steigerwalt AG, McDade JE. 1979. Classification of the Legionnaires’ disease bacterium: Legionella pneumophila, genus novum, species nova, of the family Legionellaceae, familia nova. Ann Intern Med 90:656658.[PubMed]
147. Newton HJ, Ang DK, van Driel IR, Hartland EL. 2010. Molecular pathogenesis of infections caused by Legionella pneumophila. Clin Microbiol Rev 23:274298.[PubMed]
148. Amsden GW. 2005. Treatment of Legionnaires’ disease. Drugs 65:605614.[PubMed]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error